Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12375436 | 0.85 | PLCG1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL4635568 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL16179582 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL12375435 | 0.79 | CA1 (0.44) | CA12CA1CA2CA3CA6 | |
| SCHEMBL277105 | 0.77 | KMT2A (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL2854265 | 0.76 | EPHX1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19106783 | 0.74 | CA12 (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL11637351 | 0.71 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL3698657 | 0.71 | CA12 (0.42) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL7814512 | 0.71 | KMT2A (0.39) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-RE50455-E1 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-08 | — | — | US | disclosed |
| US-20040225074-A1 | Adhesive compositions containing hybrid oxetane compounds | HENKEL AG & CO. KGAA (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040225070-A1 | Oxetane compounds containing maleimide functionality | HENKEL AG & CO. KGAA (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040225081-A1 | Oxetane compounds containing cinnamyl functionality | HENKEL AG & CO. KGAA (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6753434-B1 | CURABLE; CATIONIC AND ANIONIC RING OPENING OR FREE RADICAL POLYMERIZABLE | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20040048957-A1 | Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups | OMNOVA SOLUTIONS INC. | 2004-03-11 | — | — | US | disclosed |
| EP-1389224-A2 | POLYMERIC SURFACTANTS DERIVED FROM CYCLIC MONOMERS HAVING PENDANT FLUORINATED CARBON GROUPS | Omnova Soltions Inc (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6660828-B2 | Powder coating; fluorinated polyoxetanes; addition-condensation copolymer | OMNOVA SOLUTIONS INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030109662-A1 | Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups | DEUTSCHE BANK TRUST COMPANY AMERICAS | 2003-06-12 | — | — | US | disclosed |
| US-20030092862-A1 | Fluorinated short carbon atom side chain and polar group containing polymer, and flow, or leveling, or wetting agents thereof | OMNOVA SOLUTIONS INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002092660-A2 | POLYMERIC SURFACTANTS DERIVED FROM CYCLIC MONOMERS HAVING PENDANT FLUORINATED CARBON GROUPS | OMNOVA SOLTIONS INC (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20040225081-A1 | Oxetane compounds containing cinnamyl functionality | DUOX2, OXER1, OXGR1 | ALDH1A1 2461/4885CYP3A4 101/4885CYP2C9 115/4885 |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2886/4885CYP3A4 1988/4885CYP2C9 1148/4885 |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | ALDH1A1 2878/4885CYP3A4 2193/4885CYP2C9 2231/4885 |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885CYP3A4 2881/4885CYP2C9 3021/4885 |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2099/4885CYP3A4 2648/4885CYP2C9 3500/4885 |
| US-20040225070-A1 | Oxetane compounds containing maleimide functionality | OXGR1, DUOX2, JMJD6 | ALDH1A1 2841/4885CYP3A4 121/4885CYP2C9 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.